Screener
ArriVent BioPharma, Inc. AVBP Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Right of use assets – operating leases | 370 | 13 |
| Deferred offering costs | 69 | 69 |
| Other assets | 156 | 190 |
| Total assets | $349,295 | $333,169 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,727 | $5,934 |
| Accrued expenses | 16,169 | 19,997 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s total assets?
- ArriVent BioPharma, Inc. (AVBP) reported total assets of $349.3M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s total assets changed year-over-year?
- ArriVent BioPharma, Inc.'s total assets increased by 62.1% year-over-year, from $215.5M to $349.3M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s total assets?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s total assets has grown at a 42.9% compound annual growth rate (CAGR), from $163.1M to $333.17M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about ArriVent BioPharma, Inc.'s total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude